http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1221407-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30633d35fa5989a194b4d8ef00702eb4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-91 |
| filingDate | 1969-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1971-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1221407-A |
| titleOfInvention | 0,2,3,4-tetrahydro-7-substituted-6-sulfamyl-4-quinazolinones, process for preparing the same and pharmaceutical compositions comprising the same |
| abstract | 1,221,407. Quinazolinone derivatives. WALLACE & TIERNAN Inc. 28 Feb., 1969 [29 Feb., 1968], No. 11001/69. Heading C2C. Novel compounds (I) (including salts thereof) wherein R 1 signifies H, alkyl or phenylalkyl, R 2 signifies ÀCO 2 H, Àalkyl À CO 2 H, À alkyl À CO 2 À optionally halo substituted alkyl, À CO 2 À alkyl (including cycloalkyl), À CONH 2 , À alkyl ÀCONH 2 , . CONH . alkyl, À alkyl À CONH alkyl, À CON À (alkyl) 2 , À CO À N = A or À alkyl À CO À N = A (N=A signifies a heterocyclic ring), R 6 and R 9 signify H, alkyl, alkoxy, alkoxyalkyl, OH, NH 2 , CN, or alkylamino, R 7 and R 8 signify H, alkyl or aralkyl or together with the adjacent nitrogen comprise a heterocyclic ring, X signifies halogen, CF 3 or CN, R 3 , R 4 and R 5 signify H, OH, alkyl, alkoxy, alkoxyalkyl, NH 2 , SO 2 NH 2 , CN, CF 3 or halogen and n is 0, 1, 2, 3 or 4, are obtained: (a) by reacting an amide (II): with an aldehyde, R 2 ÀCHO, or with an acetal thereof (hydrogenation and alkylation may subsequently be utilized to, respectively, replace a 1-benzyl group by a hydrogen atom and to alkylate the 6-sulphamoyl group); or (b) by reducing an unsaturated quinazolinone with sodium borohydride. Pharmaceutical preparations showing diuretic activity contain as active ingredient compounds (I); administration is orally, interperitoneally and intravenously. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0057763-A1 |
| priorityDate | 1968-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.